Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Massachusetts General Hospital
Fujian Medical University
Thomas Jefferson University
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
Sumitomo Pharma America, Inc.
Corewell Health West
University Hospital Heidelberg
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Gilead Sciences
University of California, Davis
Array BioPharma
University of Arizona
M.D. Anderson Cancer Center
Swiss Cancer Institute
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)
Memorial Sloan Kettering Cancer Center
Dartmouth-Hitchcock Medical Center
Indiana University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
European Myeloma Network B.V.
Dana-Farber Cancer Institute
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Case Comprehensive Cancer Center
Janssen-Cilag B.V.
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Janssen-Cilag B.V.
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
PETHEMA Foundation
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
University of Kentucky
Massachusetts General Hospital
University of Bologna